Syneron said that during the “go-shop” period, it solicited 59 potential buyers, with 2 potential bidders negotiating and entering into a confidentiality agreement with Syneron. However, the company said it did not receive any acquisition proposals.
“Syneron Candela did not receive any alternative acquisition proposals during the “go-shop” period, including from the two parties who entered into confidentiality agreements and subsequently confirmed they were not interested in pursuing an acquisition of Syneron Candela,” the company wrote in an SEC filing.
The company said it is hopeful that the acquisition will be completed during the 3rd quarter of 2017, subject to Syneron Candela shareholder approval and customary closing conditions.
Last month, Syneron said it inked a deal to be acquired by Apax Partners for approximately $397 million.
Through the deal, Apax Partners will pay $11 per share for all outstanding shares of Israeli aesthetic device developer Syneron. Syneron, and its Candela brand, produce aesthetic medical equipment including body contouring, hair removal and wrinkle reduction devices.
The deal was originally reported in February, with Apax reportedly looking to pick up Syneron and its aesthetic devices for between $350 million and $400 million.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.